Loading...
Loading...
APTX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 17.1M |
| Operating I/L | -17.1M |
| Other Income/Expense | -0.6M |
| Interest Income | 0.0M |
| Pretax | -17.7M |
| Income Tax Expense | 0.6M |
| Net Income/Loss | -18.2M |
Aptinyx Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of proprietary small molecules for brain and nervous system disorder treatment. Their lead product, NYX-2925, is in Phase II clinical development for painful diabetic peripheral neuropathy and fibromyalgia. Additionally, NYX-783 and NYX-458, both NMDAr modulators, are in Phase II/b clinical trials for post-traumatic stress disorder and Parkinson's disease cognitive impairment, respectively. The company generates revenue through the development and potential commercialization of these novel treatments, leveraging a research collaboration agreement with Allergan plc.
